Dx Dialogues: the next revolution in HIV care

I think that we are at the cusp of a very, very different world for people with HIV. [RELAXING MUSIC]

The first revolution really was getting HIV medicines that were super potent, super well

tolerated, resistant to resistance, easy to take. In fact, we have HIV medicines now that are injected.

And soon I bet we're really close to having medicines that you can take every six months. So I do see a new world, the second revolution,

where we're going to really work hard on these metabolic issues and try to make sure that we can mitigate them in a way that

leads to people not only living longer with HIV, but living longer with HIV without having to suffer from these other chronic conditions.

So I'm looking forward to seeing better markers. We're already getting some of these data about maybe inflammatory markers like IL-6, maybe

some markers of cardiac damage that we're seeing with troponin. So we've got data from these very, very important studies

that are getting down to the nitty gritty. I'd like to see us put this all together, come up with a better risk profile that we can use clinically to say, you know what?

Really high-dose statin is for you. Or a PSSK9 is going to be really important for you, or other things that we can do to try to reduce the risk given

this inflammation, immune activation [INAUDIBLE] probably driving this in people with HIV. [AUDIO LOGO]